Stock comparison
Gyre Therapeutics
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GYRE
Gyre Therapeutics
Market cap
$587.78M
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GYRE | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 77B | LMAT |
| Benjamin Graham | 57D | 89A | LMAT |
| Philip Fisher | 60C | 81C | LMAT |
| Peter Lynch | 47D | 67B | LMAT |
| Joel Greenblatt | 44D | 56D | LMAT |
| Charlie Munger | 49D | 68D | LMAT |
| Terry Smith | 50C | 69D | LMAT |
Side-by-side metrics
| Metric | GYRE | LMAT |
|---|---|---|
| Market cap | $587.78M | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 49.6x | 36.6x |
| ROIC (TTM) | 0.43% | 9.43% |
| Gross margin | 95.09% | 72.39% |
| Net margin | -5.37% | 24.35% |
| Revenue CAGR 5y | 99.65% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GYRE leads on
- P/E (TTM)-vs 37.1x+141%
- Debt / Equity0.0xvs 0.5x+98%
- Revenue CAGR 5y99.65%vs 12.75%+87%
- Gross margin95.09%vs 72.39%+24%
LMAT leads on
- Net margin24.35%vs -5.37%+122%
- Dividend yield0.84%vs 0.0%+100%
- ROIC (TTM)9.43%vs 0.43%+95%
- Market cap$2.23Bvs $587.78M+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.